
Today on Drug Discovery & Development
Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
A new foundation model called GREmLN from a Columbia and Chan Zuckerberg Biohub team, delivers superior cell-type classification with only 10.3 million parameters, outpacing rivals like the 100-million-parameter scFoundation. Released July 9 on bioRxiv, it taps gene regulatory networks to achieve a 0.929 macro F1 score on immune cell data. “Instead of using large language…New treatment paradigms in oncology: Highlights from the ASCO 2025 annual meeting
As in previous years, the 2025 ASCO Annual Meeting showcased a strong portfolio of practice-changing data across a wide range of tumor types. Combination therapies remain a central theme, continuing to drive meaningful improvements in clinical outcomes. These benefits are increasingly balanced by evolving strategies for managing adverse events, underscoring the field’s commitment to both…Drug Discovery and Development See More >

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
A new foundation model called GREmLN from a Columbia and Chan Zuckerberg Biohub team, delivers superior cell-type classification with only 10.3 million parameters, outpacing rivals like the 100-million-parameter scFoundation. Released July 9 on bioRxiv, it taps gene regulatory networks to achieve a 0.929 macro F1 score on immune cell data. “Instead of using large language…
Sponsored Content See More >
Genomics/Proteomics See More >

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
A new foundation model called GREmLN from a Columbia and Chan Zuckerberg Biohub team, delivers superior cell-type classification with only 10.3 million parameters, outpacing rivals like the 100-million-parameter scFoundation. Released July 9 on bioRxiv, it taps gene regulatory networks to achieve a 0.929 macro F1 score on immune cell data. “Instead of using large language…

Spatial biology: Transforming our understanding of cellular environments

Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials

Genomics in 2025: How $500 whole genome sequencing could democratize genomic data

St. Jude pioneers gene editing and structural biology to advance pediatric research
Infectious Disease See More >

Six leading medical organizations sue RFK Jr. over vaccine recommendations
Several leading medical organizations filed a lawsuit against Robert F. Kennedy Jr. on Monday, claiming that recent decisions to stop recommending vaccines to pregnant women and children are unscientific and harmful to the public. The suit was filed in the U.S. District Court for the District of Massachusetts. The American Public Health Association (APHA), the…

RFK’s new ACIP changed longstanding vaccine recommendations

Secretary of Health removes all current members of the CDC advisory committee on immunization practices

FDA COVID booster pullback jolts vaccine stocks before gains cool

Pregnancy associated with less long COVID: Researchers call for studies on protective biology
Oncology See More >

New treatment paradigms in oncology: Highlights from the ASCO 2025 annual meeting
As in previous years, the 2025 ASCO Annual Meeting showcased a strong portfolio of practice-changing data across a wide range of tumor types. Combination therapies remain a central theme, continuing to drive meaningful improvements in clinical outcomes. These benefits are increasingly balanced by evolving strategies for managing adverse events, underscoring the field’s commitment to both…

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies

As some biotechs cut, Genmab unveils striking new site near Princeton

OS Therapies announces favorable FDA feedback on external control arm strategy for osteosarcoma drug
